Sweden · Delayed Price · Currency is SEK Initiator Pharma Company Description
Initiator Pharma A/S, a clinical-stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous systems.
The company is developing Pudafensine, a monoamine reuptake inhibitor that has completed a Phase IIb clinical trial primarily targeting the dopamine system for the treatment of treatment-resistant organic erectile dysfunction; a Phase IIa trial for the treatment of vulvodynia; and preclinical development for the treatment of female sexual dysfunction (FSD).
It is also developing IP2018, a monoamine reuptake inhibitor that is in Phase IIb for the treatment of psychogenic erectile dysfunction and in preclinical development for the treatment of FSD, as well as IP2016, which is in preclinical development for the treatment of depression and pain.
The company was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
| Country | Denmark |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Claus Olesen |
Contact Details
Address: Ole Maaloes vej 3 Copenhagen, 2200 Denmark | |
| Phone | 45 61 26 00 35 |
| Website | initiatorpharma.com |
Stock Details
| Ticker Symbol | INIT |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0060775872 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Claus Elsborg Olesen | Co-Founder, Chief Executive Officer and Director |
| Dr. Dan Peters Ph.D. | Co-Founder and Chief Technology Officer |
| Prof. Ulf Simonsen Ph.D. | Co-Founder, CMO and CSO |
| Dr. Mikael Thomsen M.Sc., Ph.D. | Co-Founder and Chief Development Officer |
| Dr. Torgeir Vaage Ph.D. | Chief Financial Officer |
| Dr. Allan Wehnert | Senior Vice President of Clinical and Research & Development Strategy and Portfolio Management |
| Susanne Thomsen | Head of Clin Ops |
| Rene Egebro M.Sc. | Head of CMC |